Patent Assignment
Reel/Frame 030842/0727
Assignment of Assignor's Interest
Recorded: 2013-07-19
Pages: 8
Assignor
ABBOTT HEALTHCARE PRODUCTS B.V.
Executed: 2012-10-01
Assignee
ABBVIE B.V.
WEGALAAN 9, 2132JD, HOOFDDORP, NETHERLANDS
Covered Properties
(43)
A Pharmaceutical Formulation
Patent:
5,635,213 →
Application:
08/446,799 →
Human G-Protein Coupled Receptor
Patent:
6,998,255 →
Application:
10/088,744 →
8-{4-[3-(5-Fluoro-1H-Indol-3-Yl)-Propyl]-Piperazin-1-Yl}-2-Methyl-4H-Benzo[1,4]Oxazin-3-One Mesylate with High Affinity for the Dopamine D2 Receptor and the Serotonin Reuptake Site
1,3,5-Triazine Derivatives as Ligands for Human Adenosine-A3 Receptors
4,5-Dihydro-1H-Pyrazole Derivatives Having Potent CB1-Antagonistic Activity
Thiazole Derivatives Having CB1-Antagonistic, Agonistic or Partial Agonistic Activity
Neurotensin Active 2,3,Diaryl-Pyrazolidine Derivatives
Antibodies Immunospecific for a Novel Human G-Protein Coupled Receptor Family
Solid Salts of Benzazepine Compounds and Pharmaceutical Compositions Containing Them
Stable Crystalline Form of Bifeprunox Mesylate (7-[4-([1,1'-Biphenyl]-3-Ylmethyl)-1-Piperazinyl]-2(3H)-Benzoxazolone Monomethanesulfonate)
Stable Crystalline Form of Bifeprunox Mesylate (7-[4-([1,1'-Biphenyl]-3-Ylmethyl)-1-Piperazinyl]-2(3H)-Benzoxazolone Monomethanesulfonate)
1H-Imidazole Derivatives as Cannabinoid Receptor Modulators
1-[2H-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of pain
Application:
11/085,193 →
Publication:
US 2005/0215567
8-{4-[3-(5-Fluoro-1H-Indol-3-Yl)-Propyl]-Piperazin-1-Yl}-2-Methyl-4H-Benzo[1,4]Oxazin-3-One Mesylate with High Affinity for the Dopamine D2 Receptor and the Serotonin Reuptake Site
Binding Assay Employing IGS4, a Human G-Protein Coupled Neuromedin Receptor
Polynucleotides and Expression System of a Novel Human G-Protein Coupled Receptor
Extended release formulation of 3-amino-8-(1-piperazinyl)-2H-1-benzopyran-2-one
Application:
11/178,309 →
Publication:
US 2006/0013874
2-Substituted-1-Deaza Purine Derivatives with Adenosine Receptor Modulating Activity
2-Substituted-6-Trifluoromethyl Purine Derivatives with Adenosine-A3 Antagonistic Activity
4,5-Dihydro-1H-Pyrazole Derivatives Having Potent CB1-Antagonistic Activity
[1,2,4]-Dithiazoli(Di)Ne Derivatives, Inducers of Gluthathione-S-Transferase and Nadph Quinone Oxido-Reductase, for Prophylaxis and Treatment of Adverse Conditions Associated with Cytotoxicity in General and Apoptosis in Particular
1H-imidazole derivatives as cannabinoid CB2 receptor modulators
Salicylate and Gentisate Salts of a Piperazine Compound
Glucuronate Salt of a Piperazine Compound
Sustained-Release Formulation and Uses Thereof
Sulphur Containing Pyrazole Derivatives as Selective Cannabinoid CB1 Receptor Antagonists
Combination Preparations Comprising SLV308 and a Dopamine Agonist
Combination Preparations Comprising Bifeprunox and a Dopamine Agonist
Azaindole Derivatives with a Combination of Partial Nicotinic Acetyl-Choline Receptor Agonism and Dopamine Reuptake Inhibition
1 H-Imidazole Derivatives as Cannabinoid Receptor Modulators
Embedded Micellar Nanoparticles
Compounds with a Combination of Cannabinoid-CB1 Antagonism and Acetylcholinesterase Inhibition
Compounds with a Combination of Cannabinoid CB1 Antagonism and Serotonin Reuptake Inhibition
Heterocyclic Compounds with Affinity to Muscarinic Receptors
4,5 Dihydro-(1H)-Pyrazole Derivatives as Cannabinoid CB1 Receptor Modulators
N-Oxides of Venlafaxine and O-Desmethylvenlafaxine as Prodrugs
Method for Determining the Risk of Developing a Neurological Disease
Combination Preparations Comprising SLV308 and a Dopamine Agonist
Sulphur Containing Pyrazole Derivatives as Selective Cannabinoid CB1 Receptor Antagonists
Azaindole Derivatives with a Combination of Partial Nicotinic Acetyl-Choline Receptor Agonism and Dopamine Reuptake Inhibition
Spiro Azepane-Oxazolidinones as KV1.3 Potassium Channel Blockers
Precompacted Fast-Disintegrating Formulations of Compounds with a Low Oral Bioavailability
Application:
13/140,509 →
Publication:
US 2011/0257158
Method for Determining the Risk of Developing a Neurological Disease
Application:
13/301,189 →
Publication:
US 2012/0208185
Related Assignments
(19)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Sep 13, 1996
From: NYSTROM, CHRISTER; PAALZOW, LENNART; AQUILONIUS, STEN-MAGNUS
To: NEOPHARMA PRODUCTION AB
Reel/Frame 008147/0021 →
Assignment of Assignor's Interest
Mar 22, 2002
From: DELEERSNIJDER, WILLY; NYS, GUY; VENEMA, JAKOB; BERGER, CLAUDIA
To: SOLVAY PHARMACEUTICAL B.V.
Reel/Frame 012907/0719 →
Assignment of Assignor's Interest
May 22, 2003
From: BAKKER, CORNELIS
To: SOLVAY PHARMACEUTICALS B.V.
Reel/Frame 014477/0094 →
Assignment of Assignor's Interest
Sep 24, 2003
From: LANGE, JOSEPHUS H.M.; KRUSE, CORNELIS G.; TIPKER, JACOB; STUIVENBERG, HERMAN H. VAN
To: SOLVAY PHARMACEUTICALS B.V.
Reel/Frame 014992/0606 →
Assignment of Assignor's Interest
Mar 23, 2004
From: LANGE, JOSEPHUS H.M.; KRUSE, CORNELIS G.; HERREMAN, ARNOLDUS H.J.; VAN STUIVENBERG, HERMAN H.
To: SOLVAY PHARMACEUTICALS B.V.
Reel/Frame 015775/0084 →
Assignment of Assignor's Interest
Jun 23, 2004
From: DEN HARTOG, JACOBUS A.J.; REINDERS, JAN H.; VAN SCHARRENBURG, GUUSTAAF J.M.; PRAS-RAVES, MARIA L.
To: SOLVAY PHARMACEUTICALS B.V.
Reel/Frame 015493/0732 →
Assignment of Assignor's Interest
Jun 23, 2004
From: GUSTAFSON, GARY R.
To: ARQULE, INC.
Reel/Frame 015493/0719 →
Assignment of Assignor's Interest
Oct 28, 2004
From: VAN DER EERDEN, JORIS A.; DE JONG, PAULUS P.G.; VAN DER MEIJ, PAULUS F. C.
To: SOLVAY PHARMACEUTICALS BV
Reel/Frame 015935/0763 →
Assignment of Assignor's Interest
Dec 14, 2004
From: EIJGENDAAL, IRENE; KLEIN, GERRIT; TERHORST-VAN AMSTEL, MARIA J.L.; ZWIER, KLAAS
To: SOLVAY PHARMACEUTICALS B.V.
Reel/Frame 016073/0249 →
Assignment of Assignor's Interest
Jan 14, 2005
From: EIJGENDAAL, IRENE; KLEIN, GERRITT; TERHORST-VAN AMSTEL, MARIA J.L.; ZWIER, KLAAS
To: SOLVAY PHARMACEUTICALS B.V.
Reel/Frame 016168/0540 →
Assignment of Assignor's Interest
Feb 22, 2005
From: FEENSTRA, REOLOF W.; LANGE JOSEPHUS H.M.; PRAS-RAVES, MARIA L.; KRUSE, CORNELIS G.
To: SOLVAY PHARMACEUTICALS B.V.
Reel/Frame 015760/0749 →
Assignment of Assignor's Interest
Mar 2, 2005
From: LANGE, JOSEPHUS H.M.; KRUSE, CORNELIUS G.; VAN STUIVENBERG, HERMAN V.; KEIZER, HISKIAS G.
To: SOLVAY PHARMACEUTICALS B.V.
Reel/Frame 016322/0822 →
Assignment of Assignor's Interest
Mar 22, 2005
From: BAKKER, COMELIS; GLENNON, JEFFREY C.; HESSELINK, MAYKE B.; THAETE, CLAUDIA
To: SOLVAY PHARMACEUTICALS B.V.
Reel/Frame 016406/0806 →
Assignment of Assignor's Interest
Jul 12, 2005
From: BRUINS, NICO; FRIJLINK, HENDERIK W.; DE VRIES, MICHIEL HENRICUS
To: SOLVAY PHARMACEUTICALS B.V.
Reel/Frame 016779/0991 →
Corrective Assignment to Correct the 2ND and 3RD Assignor's Name Previously Recorded on Reel 016322 Frame 0822. Assignor Confirms the Assignment.
Aug 19, 2005
From: LANGE, JOSEPHUS H.M.; KRUSE, CORNELIS G.; VAN STUIVENBERG, HERMAN H.; KEIZER, HISKIAS G.
To: SOLVAY PHARMACEUTICALS B.V.
Reel/Frame 016911/0758 →
Assignment of Assignor's Interest
Sep 7, 2005
From: KOCH, MELLE; DEN HARTOG, JACOBUS A.J.; WANNER, MARTINUS J.; KOOMEN, GERRIT-JAN
To: SOLVAY PHARMACEUTICAL B.V.
Reel/Frame 016962/0688 →
Change of Name
Jan 16, 2007
From: NEOPHARMA PRODUCTION AB
To: NEOPHARMA AB
Reel/Frame 018767/0441 →
Assignment of Assignor's Interest
Jan 17, 2007
From: NEOPHARMA AB
To: SOLVAY PHARMACEUTICALS B.V.
Reel/Frame 018767/0648 →
Change of Name
Apr 4, 2012
From: SOLVAY PHARMACEUTICALS B.V.
To: ABBOTT HEALTHCARE PRODUCTS B.V.
Reel/Frame 027986/0356 →